KEY TAKEAWAYS

  • In a preliminary survey of 17 neurology providers, 88.2% were aware of the updated 2024 McDonald criteria for MS, but only 41.2% reported changing their diagnostic approach.
  • Lack of routine MRI reporting of central vein sign and paramagnetic rim lesions was the most frequently reported implementation barrier (70.6%).
  • Limited training, restricted access to cerebrospinal fluid kappa free light chain testing, and diagnostic uncertainty in patients with vascular comorbidities presented additional challenges.

Awareness of the updated 2024 McDonald diagnostic criteria for multiple sclerosis (MS) was high among surveyed neurology providers, but gaps in neuroimaging reporting, clinician training, and biomarker availability were reported as barriers to clinical implementation, according to preliminary findings presented at the 2026 Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026). Although most respondents were familiar with the revised criteria, fewer than half had modified their diagnostic approach, highlighting differences between awareness and clinical adoption.

The cross-sectional, survey-based observational study assessed awareness, familiarity, practice changes, and perceived implementation barriers among MS specialists, general neurologists, and advanced practice providers across academic and community settings. The preliminary analysis included 17 respondents and evaluated the integration of newer diagnostic biomarkers, including central vein sign (CVS), paramagnetic rim lesions (PRL), and cerebrospinal fluid (CSF) kappa free light chains (KFLC), into routine MS assessment.

Inside the Survey Results

  • Awareness and familiarity: Overall, 88.2% of respondents were aware of the updated criteria, with 41.2% reporting high familiarity, 35.3% moderate familiarity, and 11.8% expert-level familiarity.
  • Changes in clinical practice: A total of 41.2% had already modified their diagnostic approach, and 29.4% planned to implement changes.
  • Diagnostic management: The most frequently reported effects involved communication of diagnostic certainty and follow-up frequency for clinically isolated syndrome (CIS) or radiologically isolated syndrome (RIS), each cited by 52.9% of respondents.
  • MRI reporting barriers: Lack of routine CVS or PRL reporting by radiology departments was identified by 70.6% of respondents, while 47.1% reported insufficient personal training in interpreting these findings.
  • Additional challenges: Uncertainty regarding MS-typical lesion thresholds in patients with vascular comorbidities was reported by 41.2%, and 29.4% cited institutional unavailability of KFLC testing.
  • Provider satisfaction: Overall, 58.9% expressed satisfaction with the updated diagnostic framework, including 47.1% who were satisfied and 11.8% who were very satisfied.

The preliminary findings suggest that gaps in MRI reporting, clinician training, and access to diagnostic biomarkers may complicate implementation of the 2024 McDonald criteria. Investigators highlighted the need for more standardized MRI reporting, expanded access to KFLC testing, and additional guidance for evaluating patients with vascular comorbidities. Enrollment was ongoing at the time of abstract submission, and a larger sample may provide a clearer picture of implementation challenges across clinical settings.

Source: Memon A, Wooliscroft L, Cerghet M, Nourelden A. Evaluating the awareness, clinical integration, and implementation of the updated 2024 McDonald criteria among neurology providers: a cross-sectional study. Abstract 2610. Presented at: 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026); October 21–23, 2026; Toronto, Ontario, Canada.